Silvant Capital Management LLC Sells 1,671 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Silvant Capital Management LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,676 shares of the biopharmaceutical company’s stock after selling 1,671 shares during the quarter. Silvant Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $8,060,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Root Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at $32,000. ORG Partners LLC raised its position in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ALNY shares. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Chardan Capital dropped their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday. Finally, Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $468.84.

Insider Buying and Selling

In other news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president directly owned 24,848 shares of the company’s stock, valued at $7,704,867.84. The trade was a 8.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 53,923 shares of company stock worth $18,072,087 over the last ninety days. 1.20% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 0.5%

ALNY opened at $320.42 on Wednesday. The firm’s 50 day simple moving average is $341.06 and its two-hundred day simple moving average is $407.61. The company has a market capitalization of $42.49 billion, a PE ratio of 187.38 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the firm earned ($0.65) EPS. The company’s revenue was up 84.9% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.